Abiopharma

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000086 Size: 4 KB

New Form 8-K - STEPAN CO Filed: 2025-06-09 AccNo: 0001193125-25-137427 Size: 151 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000084 Size: 5 KB

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000082 Size: 4 KB

New Form 6-K - CollPlant Biotechnologies Ltd Filed: 2025-06-09 AccNo: 0001213900-25-052316 Size: 53 KB

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000080 Size: 5 KB

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000078 Size: 4 KB

New Form 4 - Evolent Health, Inc. Filed: 2025-06-09 AccNo: 0001628908-25-000076 Size: 5 KB

New Form 8-K - Axsome Therapeutics, Inc. Filed: 2025-06-09 AccNo: 0000950170-25-083441 Size: 270 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - HARROW, INC. Filed: 2025-06-09 AccNo: 0001641172-25-014234 Size: 380 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Harrow Acquires U.S. Commercial Rights toBYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

NewAmsterdam Pharma Announces Positive ToplineAlzheimer’s Disease Data from BROADWAY Clinical Trial

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Stepan Company Announces Appointment of New Director